{
    "clinical_study": {
        "@rank": "146566", 
        "brief_summary": {
            "textblock": "The objective of this study is to demonstrate that rPAF-AH is safe and reduces 28 day all\n      cause mortality in patients with severe sepsis."
        }, 
        "brief_title": "Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis", 
        "completion_date": "December 2004", 
        "condition": "Sepsis", 
        "condition_browse": {
            "mesh_term": [
                "Sepsis", 
                "Toxemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a randomized, double-blind, placebo-controlled, multicenter study of rPAF-AH\n      compared to placebo in patients with severe sepsis.  Eligible patients from investigative\n      sites located throughout the United States and other countries will be randomized to receive\n      either rPAF-AH or placebo administered daily for five consecutive days by intravenous (IV)\n      infusion.  All patients will be evaluated for safety and efficacy endpoints over 28 days.  A\n      follow-up evaluation will occur approximately 6 months after Day 28 to assess functional\n      status and quality of life."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          -  Clinical diagnosis of severe sepsis\n\n          -  At least 18 years old\n\n          -  Patient or legally authorized representative able to provide informed consent\n\n        Exclusion criteria\n\n          -  Severe lung injury (acute respiratory distress syndrome)\n\n          -  Immunocompromised\n\n          -  Severe liver disease\n\n          -  Inflammation of the pancreas, organ rejection, or burns to more than 30% of body\n\n          -  Enrolled in another clinical trial\n\n          -  Already participated in this or other rPAF-AH study\n\n          -  There is not a commitment to aggressive treatment\n\n          -  Has a disease with life expectancy less than 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "2500", 
        "firstreceived_date": "May 20, 2002", 
        "id_info": {
            "nct_id": "NCT00037687", 
            "org_study_id": "BAR03", 
            "secondary_id": "BB-IND 9538"
        }, 
        "intervention": {
            "intervention_name": "rPAF-AH", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Severe sepsis", 
            "Platelet-activating factor acetylhydrolase"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bothell", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98021"
                }, 
                "name": "Mary E. Lonien, M.S."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase\u00ae) for Reducing 28 Day All Cause Mortality in Patients With Severe Sepsis", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "citation": "The Pafase Phase II ARDS Prevention Study Group. Recombinant platelet-activating factor acetylhydrolase (Pafase) decreases the incidence of acute respiriatory distress syndrome (ARDS) and 28 day all cause mortality (Abstract). Intensive Care Med (2000); 26: S321."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037687"
        }, 
        "source": "ICOS Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Suntory Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "ICOS Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2003"
    }, 
    "geocoordinates": {
        "Mary E. Lonien, M.S.": "47.762 -122.205"
    }
}